After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program ...

To keep the resources flowing to this new strategy, Sionna is reducing its headcount by around 46%, including the departure ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...

A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum ...

Axoltis Pharma announced today that its phase 2 trial for amyotrophic lateral sclerosis (ALS) has missed its primary endpoint ...

Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s Afib device Laminar program for an undisclosed price. The Laminar device focuses on a catheter-based left ...

Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in ...

A monthly GLP-1 drug has been a long-running ambition at Novo. A few months before the Ascendis deal in 2024, the Danish pharma scrapped a once-monthly dual GLP-1/GIP receptor agonist over ...

Cellectis is also switching over to in vivo, channelling its resources to two preclinical candidates: HEAL-101, an in vivo ...

Accessibility came up again and again during the hearing, largely because the FDA listed a requirement in a July guidance that if the lead monitor of a psychedelic dosing session is not a physician, ...

With Novo axing monlunabant, Corbus has a chance to establish CRB-913 as the frontrunner in the CB1 race. The phase 1b data ...